David A. Siegel Esperion Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 3,569,700 shares of ESPR stock, worth $7.92 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,569,700

Previous 2,146,600 66.3%

Holding current value

$7.92 Million

Previous $6.42 Million 49.05%

% of portfolio

0.02%

Previous 0.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $2.87 Million - $4.3 Million	1,423,100 Added 66.3%	3,569,700 $9.57 Million
Q4 2023 Feb 14, 2024	BUY	$0.73 - $3.08 $445,519 - $1.88 Million	610,300 Added 39.73%	2,146,600 $6.42 Million
Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $817,217 - $1.52 Million	851,268 Added 124.27%	1,536,300 $1.51 Million
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $206,601 - $303,015	-172,168 Reduced 20.08%	685,032 $952,000
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $815,848 - $4.08 Million	-558,800 Reduced 39.46%	857,200 $1.36 Million

Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $1.69 Million - $2.82 Million	331,700 Added 30.59%	1,416,000 $8.82 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $5.84 Million - $8.71 Million	1,070,900 Added 7991.79%	1,084,300 $7.27 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $63,917 - $89,378	13,400 New	13,400 $85,000
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $2.07 Million - $3.49 Million	-58,400 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $3.29 Million - $4.53 Million	-95,400 Reduced 62.03%	58,400 $2.14 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $3.46 Million - $4.52 Million	86,300 Added 127.85%	153,800 $7.16 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $834,288 - $1.11 Million	20,800 Added 44.54%	67,500 $2.71 Million
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $1.73 Million - $2.76 Million	46,700 New	46,700 $2.15 Million
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $771,060 - $1.63 Million	-21,300 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $178,038 - $218,052	-2,700 Reduced 11.25%	21,300 $1.54 Million
Q4 2017 Feb 14, 2018	BUY	$43.47 - $67.43 $399,924 - $620,356	9,200 Added 62.16%	24,000 $1.58 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $648,240 - $780,996	14,800	14,800 $742,000

Others Institutions Holding ESPR

# of Institutions

174

Shares Held

125M

Call Options Held

2.08M

Put Options Held

1.01M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $148M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account